Summary
BACKGROUND: Short description of the pathogenicity of zygomycetes. PATIENT AND METHODS: The patient was observed both clinically and by MRI over a period of two years, starting with the first presentation. RESULTS: Description of the applied and rejected diagnostic and therapeutic options and their results. CONCLUSION: In spite of repeated interruptions of treatment the patient was able to maintain a subjective high quality of life over a period of two years. Visual acuity of the right eye amounts to 1.0 s.c., the left eye became blind one week after the first presentation.
Zusammenfassung
HINTERGRUND: Kurze Darstellung der Pathogenität von Zygomyzeten. PATIENT UND METHODE: Der Patient wurde von der Erstvorstellung über 2 Jahre hinweg klinisch und mittels MRT beobachtet. ERGEBNISSE: Die eingesetzten und abgelehnten Diagnose- und Therapiemöglichkeiten und deren Resultate werden dargestellt. SCHLUSSFOLGERUNG: Trotz mehrmaligem Abbruch der Therapie hat sich der Patient 2 Jahre nach Erkrankungsbeginn eine gute subjektive Lebensqualität erhalten. Der Visus rechts beträgt 1,0 s.c., das linke Auge erblindete 1 Woche nach Erstvorstellung.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Roden M M, Zaoutis TE, Buchanan W L, KnudsenTA, Sarkisova T A, Schaufele RL, Sin M, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ (2005) Epidemiology and outcome of Zygomycosis: a review of 929 reported cases. Clin Infect Dis 41: 643–653
Rutar T, Cockerham KP (2006) Periorbital zygomycosis (mucormycosis) treated with posaconazol. Am J Ophthalmol 142 (1): 187–188
Rogers T R (2008) treatment of zygomycosis: current and new options. J Antimicrob Chemother 61 [Suppl 1]: 135–139
Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, Gilroy N, Chu J, Shaw DR (2008) Recommendations for the treatment of established fungal infections. Int Med J 38: 496–520
Jayalakshmi SS, Reddy RG, Borgohain R, Subramanyam C, Panigrahi M, Sundarm C, Meena AK, Mohandas S (2007) Predictors of mortality in rhinocerebral mycosis. Neurology India 55 (3): 292–297
Mohr J, Johnson M, Cooper T, Lewis J, Ostrosky-Zeichner L (2008) Current options in antifungal pharmacotherapy. Pharmacotherapy 28 (5): 614–645
Lai C-C, Tan C-K, Huang Y-T, Shao P-L, Hsueh P-R (2008) Current challenges in the management of invasive fungal infections. J Infect Chemother 14: 77–85
Brown J (2005) Zygomycosis: an emerging fungal infection. Am J Health-System Pharmacy: 12/21/2005
Greenberg R N, et al (2006) Posaconazol as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50: 126–133
Van Burik J-A H, Hare RS, Solomon HF, Corrado ML, Kontoyannis DP (2006) Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42: e61–65
Kontoyannis DP, Lewis RE (2006) Invasive zygomycosis: update on pathogenesis, clinical manifestations and management. Infect Dis Clin North Am 20: 581–607
Pak J, et al (2008) Mucormycosis in immunochallenged patients. J Emergencies, Trauma and Shock 1 (2): 106–113
Ibrahim AS, et al (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117 (9): 2649–2657
Ibrahim AS, Spellberg B, Edwards J (2008) Iron aquisitation: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21: 620–625
Kaur IP, Rana C, Singh H (2008) Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther 24 (5): 481–493
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gruber, I., Lackinger, B. Verlaufsbeobachtung einer rhinozerebralen Zygomykose bei einem nur teilweise complianten Patienten. Spektrum Augenheilkd. 24, 162–165 (2010). https://doi.org/10.1007/s00717-010-0400-3
Issue Date:
DOI: https://doi.org/10.1007/s00717-010-0400-3